reports
- Wedbush Research
VMW VMWARE INC. CLASS A
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
CCS CENTURY COMMUNITIES INC.
BBY BEST BUY CO. INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
HPE HEWLETT PACKARD ENTERPRISE CO.
VFC V.F. CORPORATION
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
ZS ZSCALER INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
DELL DELL TECHNOLOGIES INC CLASS C
DAWN DAY ONE BIOPHARMACEUTICALS INC
MRVL MARVELL TECHNOLOGY INC
STX SEAGATE TECHNOLOGY HLDGS PLC
GFS GLOBALFOUNDRIES INC
- Matt Quigley
- Tom Nikic
Cross Country Healthcare Inc: 1 director
A director at Cross Country Healthcare Inc sold 13,657 shares at 14.820USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
IN8bio to Present at International Society for Cell & Gene Therapy (IS...
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada. “ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular therapies,” said Dr. Kate Rochlin, Chief Operating Officer of IN8bio. “Our presentations represent a signi...
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Gliobla...
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 31st - June 4th in Chicago, Illinois. INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or che...
- Wedbush Research
WSM WILLIAMS-SONOMA INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BBY BEST BUY CO. INC.
AXTI AXT INC.
NFLX NETFLIX INC.
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
VFC V.F. CORPORATION
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
SRRK SCHOLAR ROCK HOLDING CORPORATION
SMCI SUPER MICRO COMPUTER
WOOF INC.
STX PETCO HEALTH AND WELLNESS
SEAGATE TECHNOLOGY HLDGS PLC
- Matt Quigley
- Tom Nikic
Immersion Signs License Agreement with Samsung Electronics Co.
AVENTURA, Fla.--(BUSINESS WIRE)-- Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of patents for haptics, today announced that it has renewed a license with Samsung Electronics Co. to continue to make Immersion’s patents available to Samsung and its affiliates. “We are delighted to extend Samsung’s license to our patents for the delivery of high-quality haptics in their devices,” said Eric Singer, Immersion’s President and CEO. Immersion’s high-quality touch feedback technology enhances gaming, computing, device interactions, peripheral use, and software experiences....
Potbelly Corporation to Participate in Upcoming Investor Conferences
Potbelly Corporation to Participate in Upcoming Investor Conferences CHICAGO, May 22, 2024 (GLOBE NEWSWIRE) -- Potbelly Corporation (NASDAQ:) (“Potbelly” or the “Company”), the iconic neighborhood sandwich shop concept, today announced that Bob Wright, President and Chief Executive Officer, and Steve Cirulis, Senior Vice President and Chief Financial Officer, will participate in upcoming investor conferences. On May 29, 2024, the Company will hold one-on-one meetings with investors at the Craig-Hallum 21st Annual Institutional Investor Conference in Minneapolis, MN.On June 4, 2024, the C...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MXL MAXLINEAR INC
MU MICRON TECHNOLOGY INC.
MTH MERITAGE HOMES CORPORATION
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
DKS DICK'S SPORTING GOODS INC.
AXTI AXT INC.
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
VFC V.F. CORPORATION
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
SMCI SUPER MICRO COMPUTER
MRVL INC.
STX MARVELL TECHNOLOGY INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
GLOBALFOUNDRIES INC
- Matt Quigley
- Tom Nikic
IN8bio Announces Upcoming Presentation at 2024 European Hematology Ass...
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain. “We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after haploidentical stem cell transplantation for patients with leukemia at the upcoming EHA c...
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy...
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. In an oral presentation titled: “Healthy Donor vs. Patient Manufac...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corpora...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets - Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to newly diagnosed glioblastoma multiforme (GBM) - Dosed first patient in auto...
Immersion Corporation Reports First Quarter 2024 Results
AVENTURA, Fla.--(BUSINESS WIRE)-- Immersion Corporation (Nasdaq: IMMR), a leading developer and provider of technologies for haptics, today reported financial results for the first quarter ended March 31, 2024. First Quarter Financial Summary1: Total revenues of $43.8 million, compared to $7.1 million in the first quarter of 2023. GAAP net income was $18.7 million, or $0.59 per diluted share, compared to GAAP net income of $8.3 million, or $0.25 per diluted share, in the first quarter of 2023. GAAP operating expenses of $27.2 million in the first quarter of 2024, compared to $3.8 mi...
Potbelly Corporation Reports Strong Results for First Fiscal Quarter 2...
Potbelly Corporation Reports Strong Results for First Fiscal Quarter 2024 First quarter system-wide sales growth of 1.9% and AWS of $24,250 32 additional new franchise shop commitments in the first quarter Announces $20 million share repurchase program CHICAGO, May 08, 2024 (GLOBE NEWSWIRE) -- Potbelly Corporation (NASDAQ: PBPB), (“Potbelly” or the “Company”) the iconic neighborhood sandwich shop concept, today reported financial results for its first fiscal quarter ended March 31, 2024. Key highlights for the quarter ended March 31, 2024, compared to March 26, 2023: Total revenues d...
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in New...
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM) has been successfully dosed at the Cleveland Clinic in Ohio. INB-400 is the Company’s first autologous gamma-delta T cell therapy product candidate genetically engineered to survive chem...
Freeport-McMoRan Publishes 2023 Annual Report on Sustainability
PHOENIX--(BUSINESS WIRE)-- Freeport-McMoRan Inc. (NYSE: FCX) today announced the publication of its 2023 Annual Report on Sustainability detailing its environmental, social and governance performance during the year. This report marks FCX’s 23rd year of reporting on its sustainability progress. FCX has a long history of responsible production practices and strives to embrace evolving stakeholder expectations. This press release features multimedia. View the full release here: Richard C. Adkerson, Chairman and Chief Executive Officer, said, “Our sustainability programs are at the forefront of...
IN8bio Announces Oral Presentation at the Upcoming American Society of...
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping...
Freeport-McMoRan First-Quarter 2024 Financial and Operating Results Re...
PHOENIX--(BUSINESS WIRE)-- Freeport-McMoRan Inc. (NYSE: FCX) today announced that it has posted its first-quarter 2024 financial and operating results press release on the Investor Relations page of its website at . This press release features multimedia. View the full release here: As previously indicated on its website, FCX will host a conference call today with securities analysts at 10:00 a.m. Eastern Time to discuss quarterly results. The conference call will be webcast on the Internet along with slides. Interested parties may listen to the conference call live and view the slides on th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.